Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?

In recent years, significant development in the treatment of prostate cancer has taken place. One of the most documented methods of treatment in patients characterised by a high risk of progression is a combination of radiotherapy (RT) with long-term hormone therapy (HT).

In this group of patients, neither RT alone nor HT alone allows satisfactory outcomes to be achieved, and therefore as monotherapy they are not recommended as optimal methods of treatment In this review, we summarise arguments for combining radiotherapy with hormonal therapy in high-risk prostate cancer, with an emphasis on the results of phase III trials

Contemporary oncology (Poznań, Poland) 2015 Mar 26 [Epub]

Tomasz Milecki, Andrzej Antczak, Zbigniew Kwias, Piotr Milecki

Department and Clinic of Urology and Urologic Oncology, Poznan University of Medical Science, Poznan, Poland , Department and Clinic of Urology and Urologic Oncology, Poznan University of Medical Science, Poznan, Poland , Department and Clinic of Urology and Urologic Oncology, Poznan University of Medical Science, Poznan, Poland , Chair and Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland ; Department of Radiotherapy, Greater Poland Cancer Centre, Poznan, Poland

PubMed  Full Text Article

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe